{"id":"NCT03376789","sponsor":"Mylan Inc.","briefTitle":"Mylan Insulin Glargine Study","officialTitle":"A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-29","primaryCompletion":"2018-09-25","completion":"2019-01-10","firstPosted":"2017-12-18","resultsPosted":"2022-03-03","lastUpdate":"2022-03-03"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"MYL-1501D product using manufacture process V","otherNames":[]},{"type":"DRUG","name":"MYL-1501D product using manufacture process VI","otherNames":[]}],"arms":[{"label":"MYL-1501D (Process V Product)","type":"ACTIVE_COMPARATOR"},{"label":"MYL-1501D (Process VI Product)","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).","primaryOutcome":{"measure":"Change in HbA1c","timeFrame":"Baseline to Week 18","effectByArm":[{"arm":"MYL-1501D (Process V Product)","deltaMin":0.18,"sd":0.055},{"arm":"MYL-1501D (Process VI Product)","deltaMin":0.15,"sd":0.053}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":108},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Gastroenteritis","Hypoglycaemia","Diarrhoea"]}}